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DOI 10.1016/j.ccr.2010.01.021SUMMARYWe genetically dissect the contribution of the most prominent downstream translational components of
mTOR signaling toward Akt-driven lymphomagenesis. While phosphorylation of rpS6 is dispensable for
cancer formation, 4EBP-eIF4E exerts significant control over cap-dependent translation, cell growth, cancer
initiation, and progression. This effect is mediated at least in part through 4EBP-dependent control of Mcl-1
expression, a key antiapoptotic protein. By using an active site inhibitor of mTOR, PP242, we show amarked
therapeutic response in rapamycin-resistant tumors. The therapeutic benefit of PP242 is mediated through
inhibition of mTORC1-dependent 4EBP-eIF4E hyperactivation. Thus, the 4EBP-eIF4E axis downstream of
mTOR is a druggable mediator of translational control and Akt-mediated tumorigenesis that has important
implications for the treatment of human cancers.INTRODUCTION
The phosphoinositide 3-kinase (PI3K) signaling pathway is one
of the most frequently deregulated pathways found in cancer.
A major downstream target of PI3K is the serine/threonine
kinase Akt (Cantley, 2002). Akt was first identified as an onco-
gene transduced by a murine retrovirus that induces thymic
lymphomas (Staal, 1987). Akt is frequently hyperactivated in
human solid tumors and hematologic malignancies (Yuan and
Cantley, 2008). The mammalian target of rapamycin (mTOR)
kinase is a key downstream transducer of this signaling
pathway that links upstream nutrient availability and growth
factors to the control of cell growth and protein synthesisSignificance
The distinct functional contribution of key translational compo
pathway on tumorigenesis remains unresolved. We demon
dispensable for Akt-mediated lymphomagenesis, eIF4E plays
growth, and tumorigenesis. eIF4E controls survival of T cell p
Mcl-1, a key antiapoptotic protein. These findings provide a m
cin in the treatment of many human cancers. Indeed, we show i
the therapeutic efficacy of an ATP active-site inhibitor of mTO(Figure 1A) through phosphorylation of key translational compo-
nents (Kim et al., 2002; von Manteuffel et al., 1997). The mTOR
kinase assembles with either Raptor or Rictor to generate two
functionally distinct complexes, mTOR complex 1 and 2
(mTORC1 and mTORC2), respectively (Guertin and Sabatini,
2007). The two most prominent and well-characterized transla-
tional regulators activated by the mTOR kinase, downstream of
mTORC1, are eIF4E binding proteins 4EBP1, 4EBP2, and
4EBP3 (4EBPs) and ribosomal protein S6 (rpS6) (Figure 2A)
(Hay and Sonenberg, 2004). 4EBP1 is the most studied of all
4EBPs and is a known binding partner of eIF4E, a key rate-
limiting initiation factor for cap-dependent translation. Phos-
phorylation of 4EBP1 by mTORC1 leads to its dissociationnents activated by the oncogenic PI3K-Akt-mTOR signaling
strate that, surprisingly, while phosphorylation of rpS6 is
a critical function in control of protein synthesis rates, cell
rogenitors, at least in part, through translational control of
echanistic rationale for the therapeutic inefficacy of rapamy-
n vivo that inhibition of the 4EBP1/eIF4E axis is important for
R (PP242) in treating rapamycin-resistant tumors.
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Figure 1. The Ability of PI3K-Akt-mTOR Signaling to Augment Protein Synthesis Is Necessary for Its Oncogenic Potential
(A) Schematic representation of the PI3K-Akt-mTOR pathway and the genetic strategy to restore protein synthesis to normal levels using amouseminutemutant,
haploinsufficient for ribosomal protein L24.
(B) Cell size analysis of thymocytes from the indicated genotypes (**p < 0.00001; *p < 0.0009, n > 5/genotype).
(C) Protein synthesis levels in thymocytes measured by [35S]-methionine incorporation and TCA precipitation. The graph represents percentage of increase over
WT levels (n = 6/genotype). *p = 0.0006 and **p = 0.008.
(D) Transgenic CMV-Cap-HCV-IRES animals harboring a translational dicistronic luciferase reporter.
(E) CMV-Cap-HCV-IRES mice were crossed with AKTT and cap-dependent translation (Renilla luciferase activity) and IRES-mediated translation (Firefly lucif-
erase activity) were measured (n = 3/genotype, p = 0.004; n.s., no statistical significance).
(F) Kaplan-Meier curve showing lymphoma-free survival in AKTT (n = 19) and AKTT;L24+/ (n = 14) mice (p = 0.0006).
Data are presented as the average ± SEM. See also Figure S1.
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Pharmacogenomic Targeting of Translational Controlfrom eIF4E and allows eIF4E to form an active initiation complex
at the 50 end of mRNAs (Ruggero and Sonenberg, 2005). The
phosphorylation of rpS6 has been used extensively as a read
out for PI3K-Akt-mTOR activation; however, its function in
protein synthesis control is poorly understood (Ruvinsky and
Meyuhas, 2006). A growing body of evidence suggests that
deregulations in protein synthesis control may be important
for tumor formation. For example, eIF4E has been shown to
act as an oncogene in vivo in transgenic mice and in adoptive
transfer models when overexpressed in combination with Myc
(Ruggero et al., 2004; Wendel et al., 2004). In addition, mTORC1
signaling has been shown to be important in Akt-mediated
cellular transformation (Skeen et al., 2006) and perturbations
in translational control have been observed downstream of
oncogenic Akt and Ras signaling (Rajasekhar et al., 2003). While
these findings implicate that deregulations in translation control
may have a causal effect in tumorigenesis, the extent to which
these changes directly contribute to cancer formation and ther-250 Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc.apeutic response downstream of PI3K-Akt-mTOR signaling
remains unresolved.
It has been difficult to genetically and pharmacologically
restore increased protein synthesis downstream of oncogenic
PI3K-Akt-mTOR signaling to normal levels. Moreover, the spe-
cific and relative contribution of the twomajor downstream trans-
lational components, 4EBPs and rpS6, in the multistep process
leading to cancer remains poorly understood. This has hindered
our understanding of the relevant downstream translational
targets of mTORC1 that may be important for therapeutic
response. Current inhibitors of mTOR, including rapamycin,
a macrolide that inhibits mTORC1 function, and rapamycin
analogs (rapalogs), show surprisingly limited clinical efficacy
(Guertin and Sabatini, 2009). Importantly, while rapamycin’s
inhibition of mTORC1 leads to dephosphorylation of rpS6,
it does not efficiently target 4EBP1 hyperphosphorylation (Choo
et al., 2008). A class of active site inhibitors of mTOR more
efficiently block 4EBP-eIF4Ehyperactivation andcap-dependent
Figure 2. Phosphorylation of 4EBP1, but Not rpS6, Is Required for Increased Protein Synthesis and Cell Size Control Downstream of
Oncogenic Akt Signaling
(A) Schematic representation of the PI3K-Akt-mTOR pathway and the genetic strategy to specifically inhibit rpS6 phosphorylation or eIF4E hyperactivation.
(B) Representative western blot analysis showing the hyperphosphorylation status of pAkt, p4EBP1, and prpS6 in AKTT thymocytes.Western blot analysis of total
Akt, 4EBP1, and rpS6 in AKTT thymocytes is included.
(C) A representative cap-binding assay to analyze eIF4E-eIF4G complex formation in thymocyte cell lysates of WT, AKTT, AKTT;4EBP1M, and 4EBP1M mice and
densitometry of eIF4G/eIF4E ratio (n = 3/genotype) (*p < 0.05; n.s., no statistical significance). The eIF4E complex bound to the cap analog m7GTP-sepharose
was pulled down and western blotted with antibodies against eIF4G and 4EBP1 revealed the relative amounts of eIF4E-associated proteins. The anti-4EBP1
antibody recognizes both the endogenous 4EBP1 and the 4EBP1M proteins.
(D) Protein synthesis rates in thymocytes derived from AKTT, AKTT;4EBP1M, and AKTT;rpS6P/mice were measured by [35S]-methionine incorporation and TCA
precipitation represented as percentage of increase over WT levels; *p = 0.0006; **p = 0.001, n > 6/genotype.
(E) Cell size analysis of thymocytes from the indicated genotypes; **p < 0.00001, n = 8; *p < 0.0007, n = 6. Data are presented as the average ± SEM. See also
Figure S2.
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Pharmacogenomic Targeting of Translational Controltranslation, although their therapeutic benefit in PI3K-Akt-mTOR-
mediated tumor formation has not been tested in vivo to date
(Feldman et al., 2009; Thoreen et al., 2009). In this work, we
both genetically and pharmacologically dissect the relevance of
increased protein synthesis downstream of oncogenic mTOR
signaling in T cell lymphomagenesis and delineate the specific
contributions of 4EBPsand rpS6phosphorylation to this process.
RESULTS
Genetic Rescue of Increased Protein Synthesis
to Normal Levels Downstream of Akt Hyperactivation
Impairs Cancer Formation
Transgenic mouse models in which the minimal Lck (leukocyte-
specific protein tyrosine kinase) promoter is used to driveexpression of constitutively activated forms of Akt1, Akt2, or
Akt3 in immature T cells develop spontaneous thymic lym-
phomas (Malstrom et al., 2001; Mende et al., 2001; Tan et al.,
2008). Thus, these animals serve as an important in vivo model
system to study Akt-mediated tumorigenesis. Mice in which
a constitutively active Akt2 is expressed in immature T cells
under the Lck promoter (herein referred to as AKTT) (Tan et al.,
2008) show an increase in cell size (Figure 1B). We asked
whether the Akt-dependent increase in cell size is associated
with an increase in general protein synthesis. Thymocytes
derived from AKTT mice exhibit an almost 50% increase in
protein synthesis compared to wild-type (WT) mice prior to
tumor formation, as assessed by [35S]-methionine incorporation
(Figure 1C). We further assessed whether Akt-induced protein
synthesis increased cap- and/or IRES-dependent translation.Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc. 251
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Pharmacogenomic Targeting of Translational ControlTo address this question, we have generated CMV-Cap-HCV-
IRES transgenic mice that stably express a genetically encoded
translational reporter for cap- and IRES-dependent translation in
all tissue types (C. Bellodi and D.R., unpublished data). CMV-
Cap-HCV-IRES mice express a bicistronic mRNA where the
first cistron (Rluc) is translated via cap-dependent translation
and the second cistron (Fluc) is translated under a cap-indepen-
dent mechanism through the Hepatitis C virus (HCV) IRES
element. The HCV IRES element provides a general readout of
IRES-dependent translation activity and therefore represents
a genetic tool to quantify differences in overall IRES-dependent
translation initiation in vivo. We observed that Akt-mediated
increases in protein synthesis rates are specifically at the level
of cap-dependent translation, as we did not observe any differ-
ence in IRES-mediated translation in AKTT;CMV-Cap-HCV-
IRES transgenic mice in vivo and with an additional bicistronic
construct containing a cellular IRES element ex vivo (Figures
1D and 1E and Figure S1A, available online). Thus, increases in
cap-dependent translation and cell size are associated with
AKT oncogenic activation.
To date, it has been difficult to genetically restore increases
in protein synthesis downstream of Akt hyperactivation to nor-
mal levels to assess their impact on cancer formation. First
described in Drosophila, a class ofminutemutants that are hap-
loinsufficient for certain ribosomal proteins show decreases in
global protein synthesis rates that are compatible with overall
tissue homeostasis (Lambertsson, 1998; Schultz, 1929). Mouse
minute mutants, such as ribosomal protein L24+/ mice, are
viable (Oliver et al., 2004) and do not show any overt differences
in B and T lymphocyte development, growth, and cell division
(Barna et al., 2008). L24+/ mice have been successfully used
as a genetic tool to restrain increases in protein synthesis in
Em-Myc mice (Barna et al., 2008). However, lowering protein
synthesis rates does not have any effect on tumorigenesis
initiated by loss of p53 function (Barna et al., 2008). These find-
ings point to the specificity and differential requirements for
increased protein synthesis downstream of oncogenic lesions
that directly impinge on translational control as an early mecha-
nism for cellular transformation. By lowering the threshold of
protein production in L24+/ mice (Figure S1B), the increased
protein synthesis rates and cell size observed in AKTT thymo-
cytes were restored to normal levels in AKTT;L24+/ mice
(Figures 1B and 1C). This enabled us to genetically address the
extent to which increases in protein synthesis play a causative
role in PI3K-Akt-mTOR-mediated tumorigenesis. AKTT mice
develop T cell lymphomas with an onset of 3 months of age.
The onset of lymphomas in AKTT;L24+/ mice is dramatically
delayed in comparison (Figure 1F). Strikingly, 80% of AKTT
mice succumb to lymphomas by 150 days, but no AKTT;L24+/
mice develop lymphomas during the same period of time.
Most importantly, over 70% of AKTT;L24+/ mice are
lymphoma-free. We ruled out the possibility that loss of function
of L24 was associated with a cellular stress response that would
induce p53 expression, contributing to the enhanced survival of
AKTT;L24+/ mice. We did not observe induction of p53 protein
levels in lymphocytes from L24+/ and AKTT;L24+/ mice
(Figure S1C). In addition, L24 haploinsufficiency does not alter
the phosphorylation status of downstream targets of the Akt
pathway, either at the steady state or in conjunction with onco-252 Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc.genic Akt signaling (Figure S1D). These genetic results demon-
strate that the ability of Akt to augment protein synthesis is
necessary for its oncogenic potential.
Genetic Dissection of Translational Components
Downstream of mTORC1 Reveals a Critical Function
for 4EBPs, but Not rpS6, in Akt-Mediated Tumorigenesis
Having established that control of protein synthesis plays a
causal role in PI3K-Akt-mTOR signaling, we next used a series
of unique genetic mouse models to assess the role of specific
translational components that are directly activated downstream
of mTOR oncogenic signaling in cancer initiation. The two most
prominent and well-characterized translational regulators acti-
vated by the mTOR kinase are the eIF4E binding proteins
4EBP1, 4EBP2, and 4EBP3 and rpS6 (Figure 2A) (Ruggero and
Sonenberg, 2005). Of the three 4EBPs, 4EBP1 is the best char-
acterized. AKTT thymocytes display an increase in both rpS6 and
4EBP1 phosphorylation levels as compared to WT controls
(Figure 2B). The phosphorylation of 4EBPs bymTOR in response
to PI3K activation causes dissociation of the cap-binding protein
eIF4E from 4EBPs and stimulates cap-dependent translation.
Phosphorylation of rpS6 is achieved by S6 kinases, which are
direct targets of mTOR (Kim et al., 2002; Kozma et al., 1990).
The role of rpS6 in translational control remains poorly under-
stood (Ruvinsky et al., 2005; Stolovich et al., 2002; Tang et al.,
2001). The lack of adequate genetic mouse models has made
it difficult to address the relative contribution of rpS6 and
eIF4E hyperactivation in translational control and tumorigenesis
downstream of oncogenic PI3K-Akt-mTOR signaling. As rpS6
and eIF4E may have constitutive functions in control of protein
synthesis required for cell viability and tissue homeostasis, we
sought to only selectively restore the consequences of their
hyperactivation downstream ofmTOR activation. To this end, we
used rpS6 phosphorylation-deficient knockin mice (rpS6P/)
(Ruvinsky et al., 2005) or a mutant 4EBP1 transgenic mouse
(see below) to restore rpS6 and eIF4E hyperactivation, respec-
tively, to normal levels downstream of oncogenic PI3K-Akt-
mTOR signaling (Figure 2A).
The 4EBP1 protein is directly phosphorylated bymTORon T37
and T46, which primes subsequent phosphorylation on S65 and
T70 (Gingras et al., 1999a, 2001). The phosphorylation of 4EBP1
by mTOR in response to PI3K activation decreases its affinity for
eIF4E, allowing eIF4G and associated factors to bind to eIF4E
(Brunn et al., 1997; Gingras et al., 1998). An increase in eIF4E
bound to eIF4G results in augmented cap-dependent translation
as the assembly of this complex triggers the recruitment of the
40S ribosomal subunit to the 50 cap, thereby initiating cap-
dependent translation (Gingras et al., 1999b). To investigate
the consequence of eIF4E hyperactivation in AKTT mice, we
generated a thymus-specific 4EBP1 phosphorylation-defective
transgenic mouse (4EBP1M), where each of the five insulin-
and rapamycin-responsive 4EBP1 phosphorylation sites have
been mutated to alanine (Figure 2A and Figures S2A–S2C). The
binding of 4EBP1 and eIF4G to eIF4E are mutually exclusive,
as they compete for the same binding site (Haghighat and
Sonenberg, 1997). As such, hypophosphorylated 4EBP1 directly
competes with eIF4G for eIF4E binding, while the hyperphos-
phorylated form is a less efficient competitor. Therefore, as
a consequence of Akt hyperactivation, the coexpression
Figure 3. Hyperactivation of eIF4E Is Essential for T Cell Lymphoma-
genesis Downstream of Oncogenic PI3K-Akt-mTORSignaling, while
Phosphorylation of rpS6 Is Dispensable
Kaplan-Meier analysis of lymphoma-free survival in two independent
cohorts of AKTT (n = 26) and AKTT;4EBP1M (n = 25) mice (A), p = 0.0001,
and AKTT (n = 19) and AKTT;rpS6P/ (n = 18) mice (B), p = 0.3319. See also
Figure S3.
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Pharmacogenomic Targeting of Translational Controlof exogenous 4EBP1M is predicted to compensate for the
decreased efficiency of the endogenous 4EBP(s) to bind eIF4E
(Avdulov et al., 2004).
At first, we analyzed the extent of the interaction between
eIF4E and eIF4G in thymocytes derived from AKTT and AKTT;
4EBP1M transgenic mice compared to their respective controls
by using a cap pull-down assay (Figure 2C). In this assay,
eIF4E present in thymocyte lysates binds tightly to sepharose
beads coated with the cap analog 7-methyl GTP (m7GTP), allow-
ing proteins bound to eIF4E to be examined. AKTT thymocytes
display hyperphosphorylation of 4EBP1, which is concomitantly
associated with an increase in eIF4E-eIF4G complex formation
(Figure 2C). Expression of the 4EBP1M transgene in thymocytes
derived fromAKTT;4EBP1Mmice selectively restores the amount
of eIF4G bound to eIF4E to normal levels (Figure 2C). Notably,
4EBP1M cells display only a slight decrease in eIF4E-eIF4G
complex formation compared to WT cells, indicating that the
4EBP1M transgene selectively inhibits eIF4E hyperactivation
downstream of oncogenic Akt signaling but does not perturb
steady-state eIF4E activity. This is consistent with the fact that
endogenous, hypophosphorylated 4EBP1 and 4EBP2 are both
highly expressed in the thymus and that at steady state
4EBP1M competes with both for eIF4E binding (Figure S2D).
These results indicate that a balance between endogenous
4EBPs and exogenous 4EBP1M proteins allows for the mainte-
nance of basic cellular functions and does not have a functional
impact on cap-dependent translation in a WT background
(Figures S1B and S2D). Indeed, 4EBP1M mutant mice do not
exhibit decreases in protein synthesis (Figure S1B) and show
normal thymopoiesis (Figure S2C). Therefore, the 4EBP1M
protein predominantly blocks eIF4E hyperactivation down-
stream of oncogenic Akt signaling. As such, 4EBP1M mice are
an important genetic tool to selectively restrain eIF4E hyperacti-
vation downstream of oncogenic Akt signaling in a tissue-
specific manner.
To determine whether phosphorylation of 4EBP1 or rpS6 by
the mTOR kinase is directly responsible for augmented protein
synthesis downstream of oncogenic Akt signaling, we inter-
crossed AKTTmice with either 4EBP1M or rpS6P/mice. Impor-
tantly, phosphorylation-deficient 4EBP1 and/or rpS6 proteins do
not exert any dominant-negative effect on mTORC1 or S6 kinase
activity, respectively (Figure S2E). The increased rate of protein
synthesis in Akt-overexpressing thymocytes prior to tumor
formation is significantly rescued in AKTT;4EBP1M mice (Fig-
ure 2D). Unexpectedly, despite the fact that rpS6P/ cells
show a 20% reduction in protein synthesis capacity compared
to WT thymocytes (Figure S1B), inhibiting phosphorylation of
rpS6 does not restore augmented protein synthesis rates
downstream of oncogenic Akt signaling. Unexpectedly, and on
the contrary, AKTT;rpS6P/ cells show an even higher rate of
protein synthesis compared to AKTT cells (Figure 2D and Discus-
sion). In agreement with these results, increased cell size evident
in AKTT thymocytes is restored to normal levels in AKTT;4EBP1M
thymocytes, but not in AKTT;rpS6P/ cells (Figure 2E). These
findings demonstrate a dichotomy of the in vivo requirement
for phosphorylation of 4EBP1 and/or rpS6 in the control of
protein synthesis downstream of oncogenic Akt signaling and
they highlight the specificity in quantitative translation control
and regulation of cell size mediated by 4EBP1.These results led us to next assess the physiological rele-
vance of eIF4E-dependent increases in protein synthesis down-
stream of Akt hyperactivation in tumorigenesis. Notably, the
onset of lymphomagenesis in AKTT;4EBP1Mmice is dramatically
delayed compared to AKTT mice and, most importantly, 60% of
AKTT;4EBP1M mice do not develop lymphomas (Figure 3A).
Interestingly, within the subset of AKTT;4EBP1M mice that even-
tually go on to develop lymphomas, increases in protein syn-
thesis are observed in these tumors (Figure S3A). These findings
suggest that additional genetic lesions can arise in a subset of
AKTT;4EBP1Mmice, which lead to increases in protein synthesis
and allow for cancer formation. In agreement with the fact
that protein synthesis and cell growth are not restrained in
AKTT;rpS6P/ mice, we did not observe any difference in lym-
phomagenesis between AKTT and AKTT;rpS6P/ mice (Fig-
ure 3B). These results demonstrate that the mTOR-4EBP1-
eIF4E arm of Akt signaling is a major and specific effector of
protein synthesis control and is critically required for PI3K-Akt-
mTOR oncogenic activity. Moreover, while phosphorylation of
rpS6 is a commonly used readout of mTOR activation, it is
dispensable for Akt-mediated tumorigenesis.Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc. 253
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Figure 4. Oncogenic PI3K-Akt-mTOR Signaling Leads to Enrich-
ment of the DN3-4 Thymic Subpopulation, which Is Dependent on
eIF4E Hyperactivity
(A) Percentage of DN3-4 thymocytes (prior to tumor formation compared to
total DN thymocytes) in the thymus, as assessed by flow cytometry (n > 5/
genotype) (*p < 0.003; **p < 0.002; and n.s., no statistical significance).
(B) Percentage of DN cell subsets in thymic tumors from AKTT mice (n = 5).
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254 Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc.Downstream of Oncogenic Akt Signaling, 4EBP-eIF4E
Specifically Controls T Cell Progenitor Survival,
at Least in Part, through Expression of the Antiapoptotic
Protein Mcl-1
We next investigated the cellular consequences of increased
eIF4E activity and protein synthesis during Akt-mediated lym-
phomagenesis. The development of T cell precursors is marked
by prescribed changes in the expression of differentiation anti-
gens CD4, CD8, CD44, and CD25, which can be used to divide
thymocytes into distinct subsets. Early thymocyte progenitors
lack CD4 and CD8 expression and are termed double-negative
(DN) cells. The DN stage is subdivided into four categories.
The DN1 stage is characterized by surface expression of CD44
(CD44+CD25). Maturation of this earliest thymocyte subset
then proceeds from the DN2 stage (CD44+CD25+) to the DN3
stage (CD44CD25+) and finally to the DN4 stage (CD44
CD25) (Shortman and Wu, 1996; Zuniga-Pflucker, 2004). The
Lck proximal promoter that drives AKTT and 4EBP1M expression
first becomes active at the DN2 stage (Buckland et al., 2000),
and therefore the effects of oncogenic Akt must occur at this
stage or later. The DN3-4 transition is characterized by a burst
of proliferation and survival stimuli, ensuring the subsequent
differentiation of DN thymocytes to the CD4+CD8+ double-
positive and single-positive stages (Figures S4A and S4B)
(Ciofani and Zuniga-Pflucker, 2006). By analyzing the number
of individual pretumor T cell precursor subsets, we specifically
observed an increase in DN3-4 cells in the thymus of AKTT
mice, which was completely restored to normal numbers in
AKTT;4EBP1M and AKTT;L24+/ mice, but not in AKTT;rpS6P/
mice (Figure 4A). In agreement with these findings, while AKTT
tumors show an accumulation of cells at various stages of
T cell maturation, the DN3-4 cells are the most abundant and
the earliest DN cell type to contribute to thymic tumor cellularity
(Figures 4B and 4C), and this profile is phenocopied in the
subset of AKTT;4EBP1M mice that eventually develop tumors
(Figure S3B).
We next sought to further understand the cellular mechanism
by which the DN3-4 cells accumulate in AKTT mice and whether
this effect is dependent on the ability of Akt to augment protein
synthesis. To this end, we analyzed programmed cell death,
cell proliferation, and differentiation of DN3-4 cells in WT and
AKTT mice prior to tumor formation. We observed normal T cell
differentiation in AKTT mice in the OP9-DL1 culture system
where DN2 cells from AKTT mice progress to the CD4+ and
CD8+ single-positive stage (Figures S4A–S4C). Similarly, cell
proliferation of DN3-4 cells as well as all other thymic subpopu-
lations was not increased in AKTT cells (Figures S4D and S4E).
These results are in agreement with previous findings, which
demonstrate that Lck-Akt1 transgenic mice also do not display
an in vivo increase in cell proliferation (Malstrom et al., 2001).
On the contrary, proliferation of DN3-4 cells is decreased in
AKTT cells compared to WT cells and may reflect a tumor-sup-
pressive cellular response to an oncogenic insult (Figure S4D).
In addition, despite the fact that AKTT;rpS6P/ thymocytes
show an even further increase in protein synthesis levels(C) Flow cytometry analysis of all thymocyte subpopulations in thymic tumors
from AKTT mice (n = 5). Data are presented as the average ± SEM. See also
Figure S4.
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Figure 5. eIF4E Hyperactivation Downstream of Oncogenic PI3K-Akt-mTOR Signaling Impairs Programmed Cell Death of Specific T Cell
Precursors, at Least in Part, through Control of Translation of Mcl-1
(A) Percentage of Annexin V+ DN3-4 cells prior to tumor formation (n > 3 mice/genotype) (*p < 0.001, **p < 0.02, and ***p < 0.003).
(B and C) Analysis of Mcl-1 protein expression levels in total thymocytes. (Right) Representative western blot. (Left) Densitometry analysis (*p = 0.005). All repre-
sentative western blots were loaded, resolved, and transferred from the same gel.
(D) Percentage of increase of Mcl-1 expression in AKTT and AKTT;4EBP1M in the DN3-4 compartment compared to WT controls (n = 4/genotype) (*p = 0.01).
(E) Fold change of Annexin V+ in DN3-4 cells after knockdown of Mcl-1 (n > 3mice/genotype) (*p < 0.01 and n.s., no statistical significance). Data are presented as
the average ± SEM. See also Figure S5.
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advantage (Figure S4E). There is a stochastic balance between
cell death and proliferation during T lymphocyte development,
and a background level of cell death is present in all thymocyte
subpopulations (Ciofani and Zuniga-Pflucker, 2006; Mao et al.,
2007). We next examined cell death in the AKTT lymphoid
compartment and observed a specific and marked reduction
in programmed cell death in DN3-4 cells that was completely
restored to background levels in AKTT;4EBP1M and AKTT;L24+/
mice (Figure 5A). These findings are consistent with the observa-
tion that combined loss of Akt1 and Akt2 results in increased cell
death of DN3-4 thymocytes (Juntilla et al., 2007). Altogether,
these results illustrate the importance of Akt-mediated cell
survival as a mechanism for lymphomagenesis at a stage of
lymphocyte development that normally relies on Akt for their
proper development.
To understand the molecular mechanism by which DN3-4
cells from AKTT mice are more resistant to programmed cell
death, we undertook a candidate gene approach to examine
whether increases in cap-dependent protein translation might
alter the posttranscriptional expression of specific antiapoptoticproteins. While we did not detect any changes in the protein
expression levels of six important antiapoptotic factors (Fig-
ure S5A), we observed that Mcl-1 was specifically upregulated
in AKTT cells compared to WT controls at the protein, but not
the mRNA level (Figures 5B and Figure S5B). Moreover, Mcl-1
protein degradation is not affected in AKTT thymocytes (Fig-
ure S5C). Importantly, Mcl-1 has been shown to be a critical
regulator of cell death in early thymocyte progenitors, including
DN3-4 cells (Opferman et al., 2003). Mcl-1 has also been
reported to be a translationally regulated gene, and its expres-
sion is affected by eIF4E phosphorylation in primary fibroblasts
and tumors associated with loss of Tsc2 (tuberous sclerosis 2
protein) (Mills et al., 2008). We next tested whether increases
in Mcl-1 protein levels downstream of oncogenic Akt signaling
are the result of increases in protein synthesis and/or eIF4E
hyperactivation. Mcl-1 protein expression is restored to normal
levels specifically in AKTT;4EBP1M and AKTT;L24+/, but not in
AKTT;rpS6P/ (Figures 5B and 5C and Figures S5D and S5E).
Furthermore, Mcl-1 is specifically enriched in DN3-4 AKTT
thymocytes, which show a cell survival advantage, and this
effect is dependent on eIF4E hyperactivation (Figure 5D). Thus,Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc. 255
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Figure 6. eIF4E Hyperactivation Is Important for AKTT
Tumor Maintenance
4EBP1M was induced in AKTT;4EBP1M mice at 10 weeks of age.
(A) Average tumor volumes (p < 0.03). Data are presented as the
average ± SEM.
(B) AKTT and AKTT;4EBP1Mmice that were imaged in a GE 3TMRI
at 10 and 14 weeks. Images from the same AKTT and AKTT;
4EBP1M mouse at 10 and 14 weeks.
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Pharmacogenomic Targeting of Translational Controlthe increase in Mcl-1 by eIF4E is specific to the 4EBP1 arm of
oncogenic mTOR and does not rely on rpS6 phosphorylation.
We next asked whether Mcl-1 was functionally important for
the increased cell survival observed in AKTT DN3-4 cells. We
screened a panel of Mcl-1 shRNAs for a candidate which would
reduceMcl-1 levels by roughly 25% in AKTT thymocytes (Figures
S5F and S5G). We observed a significant reversal of the antia-
poptotic advantage of AKTT DN3-4 cells upon knockdown of
Mcl-1 (Figure 5E). Thus, eIF4E-dependent control of Mcl-1
protein expression confers a cell survival advantage of specific
thymocyte progenitors.
eIF4E Hyperactivation Is Important for AKTT-Mediated
Tumor Maintenance
We next asked whether the maintenance of AKTT tumors relies
on activation of the 4EBP-eIF4E axis. To this end, we induced
the expression of the 4EBP1M transgene at 10 weeks of age in
AKTT;4EBP1M mice, at which time lymphomas were already
evident (Figures 6A and 6B). Subsequently, a cohort of AKTT
and AKTT;4EBP1M mice were imaged by MRI to monitor tumor
progression. Strikingly, by 14 weeks of age, AKTT mice showed
a 5-fold increase in tumor growth, while induction of the 4EBP1M
transgene led to a dramatic reduction in tumor size (Figures 6A
and 6B). These findings demonstrate that eIF4E hyperactivation
plays an important role in tumor maintenance and provide
a strong rationale for targeting eIF4E hyperactivation pharmaco-
logically downstream of oncogenic Akt.
The Therapeutic Efficacy of an Active Site Inhibitor
of mTOR that Efficiently Blocks 4EBP-eIF4E
Hyperactivation
As maintenance of AKTT tumors relies on eIF4E hyperactivation,
we next extended these genetic findings by conducting a
randomized preclinical trial of an mTOR ATP active-site inhibitor256 Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc.(PP242) that efficiently targets 4EBP1 in an AKTT
murine allograft model. Traditional allosteric mTOR
inhibitors, such as rapamycin and associated rapa-
logs, have demonstrated limited clinical efficacy
(Guertin and Sabatini, 2009). The lack of therapeutic
efficacy of rapamycin correlates with only partial inhibi-
tion of mTORC1 (Choo et al., 2008). Our genetic find-
ings, which demonstrate an essential role of 4EBP1
in cancer initiation and progression, may provide
insight into the limited therapeutic efficiency of
rapalogs. In particular, rapamycin leads to dephos-
phorylation of rpS6, but only minimally affects 4EBP1
phosphorylation. Importantly, a class of active site
inhibitors of mTOR, including PP242 and Torin1,
more efficiently block eIF4E hyperactivation and cap-dependent translation, although their therapeutic benefit has
not been tested in vivo downstream of oncogenic Akt-mTOR
activation (Feldman et al., 2009; Thoreen et al., 2009).
We tested PP242 therapeutic benefit in comparison to rapa-
mycin in an AKTT murine allograft model. This allograft approach
has a distinct advantage in monitoring for therapeutic response,
as tumor growth following administration of therapeutic com-
pounds can be directly visualized. Nude mice injected with pre-
tumor AKTT thymocytes uniformly developed disseminated
lymphoma in the lymph nodes, spleen, and liver within 20 days
(Figure 7B and data not shown). Baseline measurements of
pretreatment tumor areas were obtained on day 17 (prior to initi-
ation of therapy). Mice were randomized into three groups
(vehicle control, rapamycin, and PP242) and treatment was initi-
ated 20 days after initial injection of AKTT pretumor cells
(Figure 7A and see Experimental Procedures). After 20 days of
treatment, all groups maintained body weight demonstrating
drug tolerability and lack of noticeable toxicity (Figure 7D).
Mice treated with rapamycin mirrored the vehicle-treated cohort
with a 3-fold increase in tumor area by the end of the trial (Figures
7B and 7C). Strikingly, PP242-treated mice did not display any
tumor growth after 20 days of treatment. In addition, the meta-
static potential of the AKTT thymocytes was compromised
because, unlike vehicle and rapamycin-treated mice, PP242-
treated mice developed no new palpable lymphadenopathy
(Figure 7B, insets) and displayed significantly less leukocytosis
and splenomegaly (data not shown).
We next assessed the basis for the increased therapeutic
efficacy of PP242 compared to rapamycin.We observed a differ-
ential effect on downstream translational targets of mTORC1
in vivo (Figure 8A). Moreover, in agreement with in vitro evidence,
the mTORC2 target Akt (S473) is also inhibited in vivo (Figure 8A
and Discussion) (Feldman et al., 2009). Importantly, while rapa-
mycin only inhibits phosphorylation of rpS6, PP242 also inhibits
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Figure 7. PP242, but Not Rapamycin, Has a Significant In Vivo Anti-Tumor Effect on AKTT Tumor Allografts
(A) AKTT thymocytes were injected subcutaneously and allowed to form tumors for 20 days. 30 tumor-bearing mice were randomized into three groups of 10:
vehicle, 5 mg/kg rapamycin, or 100 mg/kg PP242. Treatments were given 7 days a week for 20 days.
(B) Representativemice from each cohort after 20 days of therapy. Dotted yellow lines, primary tumor; dotted green lines,multiple sites of lymph nodemetastasis;
green arrows (inset), areas of significant cervical lymphadenopathy.
(C) Tumor areas in square millimeters. Black line, vehicle; blue line, rapamycin; red line, PP242.
(D) Mouse weights in grams during the course of treatment. Data are presented as the average ± SEM.
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Pharmacogenomic Targeting of Translational Controlphosphorylation of 4EBP1 (Figure 8A) and was associated with
a significant decrease in protein synthesis (Figure 8B). AKTT allo-
graft tumors treatedwith PP242 display a strong cytotoxic effect,
with a marked increase in apoptotic cell death compared to
vehicle- and rapamycin-treated tumors (Figure 8C). Surprisingly,
no effect was observed in cell proliferation (Figure 8D).
We next sought to determine whether 4EBP1 is the relevant
PP242 pharmacological target, downstream of mTOR, respon-
sible for PP242-induced cell death of AKTT tumor cells. To this
end, we took advantage of the subset of AKTT;4EBP1M that
developed T cell lymphomas and treated either AKTT or AKTT;
4EBP1M tumor cells with PP242. Strikingly, AKTT;4EBP1M thy-
mocytes were insensitive to PP242 and were resistant to
apoptosis, while the majority of AKTT tumor cells undergo pro-
grammed cell death (Figure 8E). Altogether, our genetic and
pharmacological results strongly suggest that the 4EBP-eIF4E
axis is a major effector of oncogenic mTOR signaling. Moreover,
4EBP1 represents a clinically relevant target for mTOR ATP
active site inhibitors that may display greater preclinical efficacy
than rapamycin in the treatment of human cancers.DISCUSSION
Here, we genetically and pharmacologically demonstrate that
the 4EBP-eIF4E axis downstreamof oncogenicmTOR is a critical
mediator of oncogenic Akt signaling and therapeutic response to
mTOR ATP active site inhibitors. The fact that the majority of
AKTT;L24+/ mice are lymphoma-free when protein synthesis
and cell size is genetically restored to normal levels indicates
that AKTT tumor cells may be addicted to increases in protein
synthesis levels for cancer development. This is in agreement
with further genetic dissection of the role of two of the most
downstream translational regulators of oncogenic mTOR sig-
naling toward Akt-mediated tumorigenesis. Our findings demon-
strate a central role for 4EBP1 in the control of cap-dependent
protein synthesis, cell growth, and cell survival downstream of
oncogenic Akt signaling. Moreover, we identify a qualitative
effect of 4EBP1 on the expression of a specific antiapoptotic
protein, Mcl-1, that confers a survival advantage to pretumor
Akt-overexpressing DN3-4 progenitor cells. These findings are
in agreement with the fact that Mcl-1 is a critical regulator ofCancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc. 257
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Figure 8. PP242 Shows a Better Therapeutic Effect Than Rapamycin In Vivo, at Least in Part, through Inhibition of the 4EBP-eIF4E Axis
(A) Pharmacodynamic analysis of mTOR targets through western blot analysis. Each lane represents one post-treatment tumor 20 days after initiation of therapy.
(B) Protein synthesis levels in tumor thymocytes treated with DMSO, rapamycin (50 nM), and PP242 (2.5 mM) ex vivo for 2 hr measured by [35S]-methionine incor-
poration and TCA precipitation (n = 6/genotype) (*p = 0.001 and **p = 0.001).
(C) Fold decrease in cell survival compared to WT as determined by propidium iodide/Annexin exclusion (n = 10/cohort) (*p < 0.01 and **p < 0.05).
(D) Cell-cycle analysis of post-treatment tumor samples (n = 3/cohort).
(E) Fold change in live AKTT and AKTT;4EBP1M tumor cells after 24 hr treatment with PP242 (2.5 mM) ex vivo (n = 3) (*p < 0.001; n.s., no statistical significance).
Data are presented as the average ± SEM.
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Pharmacogenomic Targeting of Translational Controlcell death, specifically in early thymocyte progenitors (Opferman
et al., 2003). Moreover, while phosphorylation of rpS6 is exten-
sively used as a read-out of mTORC1 activity, we show here
that it is dispensable for transformation downstream of onco-
genic Akt signaling in the thymic compartment. Interestingly,
despite the fact that AKTT;rpS6P/ cells display an increase in
protein synthesis compared to AKTT thymocytes, this does not
translate into an increase in cell size, perhaps because AKTT
cells have already reached a maximum size threshold. In addi-
tion, in AKTT;rpS6P/ mice, there is no effect on Mcl-1 protein
production compared to AKTT (Figure S5E) and consistently
this does not translate into a further increase in cell survival
and tumorigenesis (Figures 3B and 5A). Additionally, the phos-
phorylation of rpS6 may have tissue-specific effects, as it
modifies the insulinoma phenotype associated with hyperactiva-
tion of Akt in the pancreas (Alliouachene et al., 2008).
The immunosuppressant drug rapamycin is an allosteric
partial inhibitor of mTORC1 function that has shown limited ther-
apeutic efficacy in human cancer clinical trials and a modest
tissue-specific effect on 4EBP1 phosphorylation downstream
of PI3K signaling (Choo et al., 2008; Guertin and Sabatini,
2009). On the contrary, a class of mTOR ATP active-site inhibi-
tors, such as PP242, significantly inhibit 4EBP phosphorylation
(Feldman et al., 2009; Thoreen et al., 2009). By conducting
a randomized preclinical trial of PP242 in an AKTT murine allo-258 Cancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc.graft model, we were able to test the effect of PP242 in a very
controlled and genetically relevant tumor cell type in vivo. Mirror-
ing our genetic findings, we show that complete mTOR inhibition
increases programmed cell death without significantly affecting
cell proliferation. In addition, while rapamycin is able to decrease
rpS6 phosphorylation, it is not an efficient inhibitor of 4EBP1
hyperphosphorylation and does not have a therapeutic benefit
for the treatment of AKTT tumors (Figures 8A–8D). This is in
agreement with our genetic findings showing that rpS6 is dis-
pensable for tumor growth. Importantly, we demonstrate that
the apoptotic effect of PP242 is dependent, to a large extent,
on eIF4E hyperactivation as AKTT;4EBP1M tumor cells are insen-
sitive to PP242-induced programmed cell death.
PP242 also inhibits mTORC2 kinase activity, thereby decreas-
ing the phosphorylation of Akt (s473) through a positive feed-
back loop between mTORC2 and Akt. While PP242 inhibits the
phosphorylation of Akt, this does not have an effect on the phos-
phorylation of direct Akt downstream targets, including TSC2,
FOXO1/O3a, and GSK3a/b (Feldman et al., 2009). In addition,
using Sin1/ andRictor/mouse embryonic fibroblasts, where
the mTORC2 complex is unable to phosphorylate Akt, mTOR
ATP active site inhibitors still maintain their full efficacy (Feldman
et al., 2009; Thoreen et al., 2009). In combination with our genetic
results, these findings support the central role of the 4EBP-eIF4E
axis as a vital therapeutic target in Akt-mediated tumors and
Cancer Cell
Pharmacogenomic Targeting of Translational Controlprovide a mechanistic rationale for the therapeutic inefficacy of
rapamycin in the treatment of many human cancers. By over-
coming the limitations of partial mTOR inhibition with second-
generation mTOR ATP active site inhibitors, previously unre-
sponsive Akt-dependent tumors may now exhibit dramatic
clinical responses.EXPERIMENTAL PROCEDURES
Mice and Allograft Model Preparation
TetO-FLAG-4EBP1M mice were generated using a 4EBP1 mutant construct in
which all five rapamycin-sensitive 4EBP1 phosphorylation sites (T37, T46,
S65, T70, and S82) were mutated to alanine (Mothe-Satney et al., 2000).
A FLAG tag was engineered into the 50 end of the 4EBP1M construct. FLAG-
4EBP1M was isolated from its vector by restriction digestion and ligated into
the tetO_SB vector (Leenders et al., 2000). The resulting TetO-FLAG-
4EBP1M construct was linearized by restriction digestion and microinjected
into mouse embryos, which were then implanted into female recipient mice.
Founder lines were generated, genotyped, and crossed with WT mice to verify
germline transmission. CMV-Cap-HCV-IRES transgenic mice were generated
using a pCMV-Myc-RL-HCV-IRES-FL construct. The HCV IRES element
(Yoon et al., 2006) was subcloned into pCR 2.1 (Invitrogen), digested with
EcoRI, and inserted into a pRF plasmid. The RL-HCV IRES-FL was amplified,
digested using BglII and KpnI, and inserted into the pCMV-Myc expression
vector. The resulting pCMV-Myc-RL-HCV-IRES-FL was linearized using an
Alw44I restriction enzyme and microinjected into mouse embryos, which
were then implanted into female recipient mice. Founder lines were generated,
genotyped, and crossed with WT mice to verify germline transmission. L24+/
mice were purchased from Jackson Laboratories. Transgenic Lck-Akt2 mice
where kindly provided by J.R.T. The rpS6P/mice were previously described
(Ruvinsky et al., 2005). The Lck-tTAmice were obtained from Taconic (Labrec-
que et al., 2001). All mice were maintained in the C57/BL6 background. Exper-
iments were performed with 6 week old mice unless stated otherwise. The
AKTT allograft model was generated using pretumor transgenic Lck-Akt2
thymocytes, which were dissociated in PBS supplemented with 3% fetal
bovine serum (PBS-FBS) and filtered through a 40 mm nylon mesh (BD Biosci-
ences). Thymocytes were then washed in PBS-FBS and pelleted at 3003 g for
5 minutes. 8–12 week old nude mice were injected with 2 3 106 total AKTT
thymocytes mixed in a 1:1 ratio of RPMI and matrigel. A volume of 200 ml of
the cell milieu was injected per mouse in the right subscapular region subcu-
taneously. Tumors were allowed to form for 20 days. Length and width caliper
measurements were taken every 2 to 3 days. All manipulations involving live
mice were approved by the University of California San Francisco Animal
Care and Use Committee.
Pharmacological Treatment of AKTT Murine Allograft Model
Thirty allograft mice were generated. All mice developed tumors and were
randomized on day 21 to receive vehicle, rapamycin (Wyeth) (5 mg/kg), or
PP242 (100 mg/kg) by gavage 7 days per week. PP242 was resuspended in
5% N-Methylpyrrolidone, 15% Polyvinylpyrrolidone, and 80% water. PP242
was administered at 100mg/kg, based on previous pharmacodynamic studies
and Feldman et al. (2009), in nude mice demonstrating effective inhibition of
phospho-4EBP1 and phospho-Akt. Cell-cycle analysis in tumor samples
was performed by propidium iodide staining as described below.
Analysis of Global Protein Synthesis
Total thymocytes (2 3 106) were methionine starved for 45 min by incubation
in 1 ml methionine-free RPMI medium, containing 10% dialyzed FBS.
Following starvation, 20 mCi of S35-labeled methionine was added to each
sample and the incubation continued for 1 hr. Cells were lysed and 35S-labeled
proteins were precipitated using 10% trichloroacetic acid (TCA), dried, and
measured in a scintillation counter (Beckman Coulter). Each sample was
measured in triplicate. The S35 experiments were controlled by using the
same number of cells for each set of experiments. Final comparisons were
made between each genotype (AKTT, AKTT;4EBP1M, rpS6P/, AKTT;
rpS6P/, L24+/, AKTT;L24+/) compared to the WT control.Cap-Binding Assay
Total thymocytes were lysed in buffer A [10 mM Tris-HCL (pH 7.6), 140 mM
KCl, 4 mM MgCl2, 1 mM DTT, 1 mM EDTA, and protease inhibitors, supple-
mented with 1% NP-40] and cell lysates (500 mg protein in 500 ml) were incu-
bated overnight at 4C with 50 ml of the mRNA cap analog m7GTP-sepharose
(GE Healthcare) in buffer A, under constant and gentle agitation. The protein
complex sepharose beads were washed with buffer A supplemented with
0.5% NP-40 and the eIF4E-associated complex was resolved by SDS-
PAGE and western blotting. The following antibodies were used following
the manufacturers’ instructions: rabbit anti-eIF4G (Cell Signaling), mouse
anti-eIF4E (BD Biosciences), and rabbit anti-4EBP1 (Cell Signaling).
Analysis of DN3-4 In Vivo Apoptosis and Characterization of Thymic
Tumors
To characterize the percentage of DN3-4 cells, as well as in vivo apoptosis,
equal numbers of freshly isolated thymocytes were labeled with APC-Cy7-
conjugated anti-CD4 (BDBiosciences), pacific blue-conjugated anti-CD8 (Cal-
tag), and PE-conjugated anti-TCRb antibodies (BD Biosciences) in PBS-FBS
(all antibodies diluted 1:100 v/v). Apoptotic cells were labeled with Annexin
V-FITC (BD Biosciences), following the manufacturer’s instructions. Negative
controls were set up for each sample by omission of Annexin V incubation.
Samples (106 cells) were acquired on a BD LSRII flow cytometer. Analysis
and quantification were done using the FlowJo software (version 8.7.1).
To characterize thymocyte subpopulations in tumors, cells were labeled with
APC-Cy7-conjugated anti-CD4 (BD Biosciences), pacific blue-conjugated
anti-CD8 (Caltag), FITC-conjugated anti-CD25 (BD Biosciences), APC-conju-
gated anti-CD44 (BD Biosciences), and PE-conjugated anti-TCRb antibodies
(BD Biosciences). Cells (106) were analyzed as described above.
Cell Sorting and In Vitro Differentiation of Thymocytes
Freshly isolated thymocyteswere labeled with biotin-conjugated anti-CD4 and
anti-CD8 (BD Biosciences) for 30 min at 4C, followed by labeling with anti-
biotin magnetic beads (Myltenyi Biotec) for 20 min at 4C. CD4CD8 DN
thymocytes were then isolated using AutoMACS (Myltenyi Biotec), following
the manufacturer’s instructions. DN cells were then labeled with APC-conju-
gated anti-CD44 and PE-conjugated anti-CD25 antibodies (BD Biosciences)
and CD44+CD25+ (DN2) thymocytes were isolated using a Becton Dickinson
FACS DiVa Flow Cytometer & Cell Sorter. DN2 cells were cocultured on
OP9-DL1-GFP cells (Schmitt and Zuniga-Pflucker, 2002) for 1 week. Thymo-
cyte subpopulations were then analyzed by flow cytometry as described
above, but including incubation of thymocytes with a biotinylated anti-CD45
antibody, followed by Qdot605-conjugated streptavidin. The analysis of
thymocyte subsets was done in CD45+GFP gated cells.
In Vivo Quantification of Cell Proliferation
Mice underwent two intraperitoneal injections (4 hr apart) with 1mgofBrdU (BD
Biosciences) each and thymocyteswere collected 12 hr after the second injec-
tion. Cells were labeled with APC-Cy7-conjugated anti-CD4 (BD Biosciences),
pacific blue-conjugated anti-CD8 (Caltag), and PE-conjugated anti-TCRb anti-
bodies (BD Biosciences) in PBS-FBS (all antibodies diluted 1:100 v/v). Stained
cells were washed, fixed, and processed for flow cytometry using the FITC
BrdU Flow kit (BD Biosciences), following the manufacturer’s instructions.
Cells (106) were analyzed on a BD LSRII flow cytometer and the percentage
of BrdU-positive cells was determined using the FlowJo software (version
8.7.1). Negative controls were performed with mice that did not receive BrdU.
Thymocyte Mcl-1 shRNA Knockdown
Single cell suspension generated from either WT or AKTT thymocytes were
transfected by electroporation (Amaxa) with an Mcl-1 shRNA (TTTCAAAG
ATGGCGTAACATTCAAGAGATGTTACGCCATCTTTGAAA) or a scramble
shRNA, which was cloned into the RNAi-Ready pSIREN-RetroQ-ZsGreen
construct (Clontech). Apoptosis analysis of the DN3-4 subpopulation was
acquired by flow cytometry, as described above, 12 hr after transfection.
To assess the extent of knockdown, Mcl-1 protein levels were measured in
parallel experiments by flow cytometry. To this end, thymocytes were labeled
with fluorescent antibodies against CD4, CD8, and TCRß chain (as described
above) and fixed with cytofix/cytoperm buffer (BD Biosciences) for 15 min at
4C. Cells were permeabilized for 20min and nonspecific binding was blockedCancer Cell 17, 249–261, March 16, 2010 ª2010 Elsevier Inc. 259
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a monoclonal rabbit anti-Mcl-1 antibody (Abcam) (1:100 v/v) for 20 min. Cells
were incubated with an APC-conjugated goat anti-rabbit antibody (Molecular
Probes) (1:200 v/v) for 20 min, washed, and finally resuspended in PBS for
analysis on a BD LSRII flow cytometer. Negative controls were generated by
omission of the primary antibody and by omission of both primary and
secondary antibodies, to account for background signal. Analysis was per-
formed as described above, but with additional gating in GFP+ cells. Mean
fluorescence intensity levels corresponding to Mcl-1 expression were gener-
ated using the FlowJo software.
Mcl-1 Protein Degradation Assay
WT and AKTT thymocytes were isolated as described above. 5 3 106 cells
were resuspended in media and treated with 50 mg/ml of cyclohexamide. Cells
were isolated at the indicated time points. Protein lysates were made and
resolved by SDS-PAGE followed by transfer onto PVDF as describe above.
Densitometry analysis of each western was acquired using the Bio-Rad
Molecular Imager Gel Doc XR with Quantity One v.4.6.7 software. Each lane
was first normalized to b-actin and then normalized to the no cycloheximide
treatment control.
Bicistronic Cap/IRES Luciferase Assay
WT and AKTT thymocytes were isolated as described above. Thymocytes
were transfected with the p53 IRES bicistronic vector by electroporation
(Amaxa). Cells were collected 24 hr after transfection and Firefly/Renilla activ-
ities were quantified using the Optocomp 1 luminometer (MGM Instruments).
Bicistronic mRNA levels were normalized by quantitative PCR using Rluc
50-AACGCGGCCTCTTCTTATTT-30; 50-ATTTGCCTGATTTGCCCATA-30; and
Fluc 50-GAGGTTCCATCTGCAGGTA-30; 50-CCGGTATCCAGATCCACAAC-30
primers. For in vivo analysis of Cap/IRES-induced luciferase activity, thymo-
cytes were isolated from HCV-IRES and AKTT;HCV-IRES mice and luciferase
activity was directly quantified as described above.
Statistical Analysis
All data presented as histograms refer to a mean value ± SEM of the total
number of animals analyzed across independent experiments. An unpaired,
two-tailed t test was used to determine p values for Figures 1 and 2 and
4 and 5 and ANOVA with Bonferroni’s or Tukey’s post-test was used for
Figures 6–8. Statistical analysis of lymphoma-free survival and respective p
values were determined using the Logrank test (Figure 3).
SUPPLEMENTAL INFORMATION
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